Other

Human Germline Genome Editing – Genetics bodies weigh in on debate with position paper

Daniel Lim

In an article published in American Journal of Human Genetics on 3 August 2017, an international group of 11 organisations with genetics expertise has issued a joint position statement, setting out 3 key positions on the question of human germline genome editing: At this time, given the nature and number of unanswered scientific, ethical, and Read More

BeneluxA collaboration joint pricing negotiations fail

Eveline Van Keymeulen

The first joint pricing negotiations for a medicinal product in the context of the BeneluxA collaboration with respect to health technology assessment and pricing and reimbursement have failed. On 23 May 2017, the Belgian Minister of Health announced that the Belgian National Institute for Health and Disability Insurance (RIZIV), joined by the Dutch competent authorities, Read More

Portugal and Spain strengthen collaboration with pilot project for the joint procurement of medicines

Patricia Carmona Botana

Last week, the Health Ministers of Portugal and Spain signed a letter of intent that marks the beginning of a joint procurement, funding and price negotiation initiative for medicines and medical devices in the Iberian region.  The initiative seeks to enhance cooperation in order to improve patients’ safety, patient’s access to innovative treatments, as well Read More

A CRISPR patent pool – one step closer to reality?

Robyn Trigg

In a press release on 10 July 2017, the Broad Institute announced that is has, with joint patent owners Harvard University, the Massachusetts Institute of Technology and the Rockefeller University, entered discussions about a potential CRISPR patent pool.  The institutions collectively submitted 22 patents (from 10 patent families) for consideration to be included in a Read More

Australian Government’s compensation claim against pharma patentees rumbles on…

Jin Ooi

Commonwealth of Australia v Sanofi [2017] FCA 382 is the latest development in the Australian Government’s bid to recover substantial compensation against Sanofi pursuant to cross-undertakings in damages given by Sanofi in interim injunction proceedings against Apotex. Why is the wider case of interest? The case began in 2007 when, in exchange for obtaining interlocutory Read More